Latest Tibotec Stories
Investigational Anti-thrombin Antibody Ichorcumab Strengthens Cardiovascular Disease Portfolio RARITAN, N.J., March 19, 2015 /PRNewswire/ -- Janssen Pharmaceuticals, Inc.
Clinical Candidate COVA 322 and FynomAb® Technology Platform Further Strengthen Immunology Portfolio and Capabilities ZUG, Switzerland, Aug.
New research report “KOL Insight: Hepatitis C: the Race for the First Interferon-free Regimen” elaborated by FirstWord has been recently published by Market Publishers Ltd.
HUDDINGE, Sweden, July 6, 2011 /PRNewswire/ -- Medivir AB (OMX: MVIR), is an emerging research-based specialty pharmaceutical company focused on infectious diseases. Medivir today announced that its investigational protease inhibitor TMC435 has received "Fast Track" designation by the U.S.
- Emitting flashes of light; glittering.